Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.59 |
| ▸ | HTR2A | P28223 | 10/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24110357 | 0.90 | HTR2C (0.48) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24110247 | 0.90 | HTR2C (0.48) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24110286 | 0.86 | HTR2C (0.45) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24110246 | 0.86 | HTR2C (0.45) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24109921 | 0.83 | HTR2C (0.52) | HTR2CHTR2AP2RX7ARCDK4 | |
| SCHEMBL24109927 | 0.83 | HTR2C (0.52) | HTR2CHTR2AP2RX7ARHTR1D | |
| SCHEMBL24110365 | 0.83 | HTR2A (0.39) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24110335 | 0.79 | HTR2C (0.40) | HTR2CHTR2A | |
| SCHEMBL24109967 | 0.78 | HTR2C (0.51) | HTR2CHTR2ACYP1A2P2RX7HTR1D | |
| SCHEMBL24109908 | 0.78 | HTR2C (0.51) | HTR2CHTR2ACDK4GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | HTR2C 35/4885HTR2A 10/4885CYP1A2 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.